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Serotonin (5-HT) is an important regulator of numerous aspects of ﬂatworm biology, ranging from neuromuscular function to sexual maturation and egg laying. In the parasitic blood ﬂuke Schistosoma mansoni, 5-HT targets
several G-protein coupled receptors (GPCRs), one of which has been demonstrated to couple to cAMP and
regulate parasite movement. This receptor, Sm.5HTRL, has been successfully co-expressed in mammalian cells
alongside a luminescent cAMP-biosensor, enabling pharmacological proﬁling for candidate anti-schistosomal
drugs. Here, we have utilized this assay to perform structure-activity investigations of 143 compounds containing previously identiﬁed alkaloid natural product pharmacophores (tryptamines, aporphines and protoberberines) shown to regulate Sm.5HTRL. These experiments mapped regions of the tryptamine pharmacophore
amenable and intolerant to substitution, highlighting diﬀerences relative to orthologous mammalian 5-HT receptors. Potent Sm.5HTRL antagonists were identiﬁed, and the eﬃcacy of these compounds were evaluated
against live adult parasites cultured ex vivo. Such structure-activity proﬁling, characterizing the eﬀect of various
modiﬁcations to these core ring systems on Sm.5HTRL responses, provides greater understanding of pharmacophores selective for this target to aid future drug development eﬀorts.

1. Introduction
Flatworm G-protein coupled receptors (GPCRs) are promising anthelmintic drug targets, given their role regulating movement, sexual
maturation and egg laying (Patocka et al., 2014; Saberi et al., 2016;
Chan et al., 2018; Hahnel et al., 2018). Over 200 million people
worldwide are infected with the parasitic Schistosoma ﬂatworms that
cause the disease schistosomiasis (Hotez and Fenwick, 2009). This
disease is largely treated by just one broad spectrum anti-schistosomal
drug, praziquantel (PZQ) (Andrews et al., 1983). PZQ has been enormously beneﬁcial in mitigating morbidity due to schistosomiasis and
moving towards control of this disease, but drawbacks include PZQ's
ineﬀectiveness against immature parasites (Sabah et al., 1986), frequent side eﬀects (Coulibaly et al., 2017), and cure rates that are rarely
100% eﬀective (Olliaro et al., 2011; Coulibaly et al., 2017). Reliance on
a single compound also raises the concern of emerging drug resistance.
Therefore, there is a need for new anti-schistosomal drugs, either to
supplement PZQ or to serve as an alternative in the event of treatment
failure.

∗

In the past several years, several studies have prioritized ﬂatworm
GPCRs as targets for drug development. RNAi and pharmacological
approaches have identiﬁed serotonin (5-HT) GPCRs that control ﬂatworm movement (Patocka et al., 2014; Chan et al., 2015), and GPCRs
have also been implicated in ﬂatworm sexual maturation and egg laying
(Lu et al., 2016; Saberi et al., 2016; Wang et al., 2017; Chan et al.,
2018). Additionally, while the parasite target(s) of PZQ remains undeﬁned, our recent work has shown that the active R-PZQ enantiomer
acts as a GPCR ligand, engaging human serotonergic GPCRs that regulate mesenteric vessel tone (Chan et al., 2017). Precedent for engagement of GPCRs by PZQ should prioritize development of scalable
functional assays to study ﬂatworm GPCRs in more detail. One such
approach centers upon co-expression of Gαs/Gαi coupled GPCRs with
GloSensor, a modiﬁed luciferase reporter which detects changes in
cellular cAMP levels. This assay provides a high sensitivity and realtime readout of GPCR activity that can be scaled to miniaturized
format. Previously, we optimized this methodology to enable pharmacological proﬁling of a schistosome serotonergic GPCR (Sm.5HTRL) that
controls worm movement (Patocka et al., 2014; Chan et al., 2016c).
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cat # 3917) at a density of 2.5x104 cells/well. One day later media was
removed and replaced with assay buﬀer (HBSS buﬀered with HEPES
(20 mM, pH 7.4) + BSA (0.1% w/v) and D-luciferin sodium salt (1 mg/
mL, Gold Biotechnology). Plates were equilibrated at room temperature
for 1 h, the phosphodiesterase inhibitor 3-Isobutyl-1-methylxanthine
(IBMX 200 μM, Sigma Aldrich) was added, and plates were equilibrated
for a further 30 min prior to test compound addition. Test compounds
were added and luminescence was read for 45 min on a GloMax®-Multi
Detection System plate reader (Promega) to identify agonist responses.
Plates were removed, and a maximal concentration of serotonin
(500 nM) was added to each well. Plates were immediately returned to
the plate reader and read for a further 45 min to identify compounds
with antagonist activity.
Adult schistosome mobility assays. Female Swiss Webster mice infected with S. mansoni cercariae (NMRI strain) were sacriﬁced 49 days
post infection by CO2 euthanasia. Adult schistosomes were recovered
by dissection of the mesenteric vasculature. Harvested schistosomes
were washed in RPMI 1640 supplemented with HEPES (25 mM), 5%
heat inactivated FBS (Gibco) and penicillin-streptomycin (100 units/
mL). Worms were cultured overnight (37 °C/5% CO2) in vented
100 × 25 mm petri dishes (ThermoFisher cat # 4031) containing 50 mL
of media. Movement assays were performed the next day. Male worms
were transferred to a six well dish (4–5 individual worms per well)
containing 3 mL media. For agonist assays, worms were incubated for
5 min in various concentrations of drug prior to acquiring videos of
worm movement. For antagonist assays, worms were incubated for 1 h
in test compound, and then a maximal concentration of serotonin
(200 μM) was added before videos were acquired. Imaging was performed using a Zeiss Discovery v20 stereomicroscope and a QiCAM 12bit cooled color CCD camera controlled by Metamorph imaging software (version 7.8.1.0). Recordings (1 min) were acquired at 4 frames
per second, saved as an image stack, and movement analyzed using
ImageJ software as described in (Chan et al., 2016c). Data represents
mean ± standard error for ≥3 independent experiments. Animal work
was carried out with the oversight and approval of the Laboratory
Animal Resources facility at the Medical College of Wisconsin. All animal experiments followed ethical regulations approved by the Medical
College of Wisconsin IACUC committee.

This approach implicated several classes of natural product heterocyclic
alkaloid scaﬀolds as regulators of Sm.5HTRL activity (Chan et al.,
2016b, 2016c, 2018). As natural products have a proven track record as
leads for drug development (Newman and Cragg, 2012), we subsequently performed a more extensive analysis of structure-activity relationships for ergot alkaloids (Chan et al., 2018), and here in this
study, tryptamine, aporphine and protoberberine scaﬀolds at this
parasite GPCR. As these compounds are known regulators of mammalian 5-HT receptors (Cabedo et al., 2009; Harding, 2016), the goal is to
understand pharmacophore features that determine selectivity and
potency for Sm.5HTRL to identify eﬀective small molecule tools useful
for probing schistosome biology as well as potential leads for anthelmintic development.
2. Materials and methods
Chemicals. A complete list of chemical structures and vendors for the
compounds used in this work is provided in Supplemental Table 1.
Compounds were selected from libraries sourced from the National
Cancer Institute (NCI Natural Products Set IV) as well as commercial
vendors (TimTec Natural Product Library and NDL-3000 Natural Derivatives Library). Individual compounds were also sourced from various vendors (Tocris, Sigma Aldrich, Santa Cruz, Pharmeks and Abcam,
see Supplemental Table 1 for catalog numbers) identiﬁed through
searches of the ZINC and PubChem databases. Finally, several aporphine compounds were kindly provided by Wayne Harding (CUNY).
The synthesis and activity proﬁle of these compounds against mammalian bioaminergic receptors has been reported elsewhere
(Chaudhary et al., 2009, 2011; Kapadia and Harding, 2015).
Cell culture. HEK-293 cells (ATCC CRL-1573, authenticated by STR
proﬁling) were cultured in growth media consisting of DMEM supplemented with GlutaMAX (Gibco cat # 10566016), 10% heat inactivated
fetal bovine serum and penicillin-streptomycin (100 units/mL,
ThermoFisher). GPCR functional assays were performed as described in
(Chan et al., 2018). The coding sequence for Sm.5HTRL (GenBank accession number KX150867) was codon optimized for mammalian expression and sub-cloned into pcDNA3.1 (−) between NotI and EcoRI.
Stable cell lines for the GloSensor-22F cAMP Plasmid (Promega) and
schistosome 5HTRs were selected with hygromycin (200 μg/mL) and
G418 (400 μg/mL). These lines were then cultured in DMEM supplemented with GlutaMAX, Pen-Strep, and 10% dialyzed FBS.
cAMP luminescence assays. Stable cell lines expressing the GloSensor22F construct or both GloSensor-22F and Sm.5HTRL were cultured in T75 ﬂasks. The day prior to performing assays, cells were trypsinized
(TrypLE Express, Gibco) and plated in solid white 96 well plates (Costar

3. Results
The schistosome serotonin (5-HT) receptor Sm.5HTRL was expressed in mammalian HEK-293 cells alongside the GloSensor 22-F
cAMP luminescent reporter (Chan et al., 2016a, 2016c). Addition of 5HT caused a rapid increase in cAMP-dependent luminescence in cells

Fig. 1. Functional expression of Sm.5HTRL. (A) Kinetics and (B) dose-response curves for 5-HT evoked luminescence in Sm.5HTRL expressing cells (solid symbols)
and a negative control cell line lacking Sm.5HTRL (open symbols). (C) Pharmacophores assayed for activity against Sm.5HTRL. Ring systems are shown with
numbering referred to throughout this manuscript. Clockwise from top - tryptamine, protoberberine, aporphine (benzylisoquinoline scaﬀold highlighted in bold).
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inhibition curves were generated from hits that blocked 5-HT evoked
cAMP generation, as well as related analogs with substitutions to provide insight into structure-activity relationships at Sm.5HTRL. In total,
concentration-response curves were generated for 83 aporphines, and
this compound series demonstrated a gradation of inhibitory potencies
at Sm.5HTRL (Fig. 3A). A subset of 9 ligands (Fig. 3A) were identiﬁed
with an IC50 ≤ 500 nM (inhibition of 500 nM 5-HT, a maximal concentration) and calculated aﬃnity, pKi≥7.0, estimated using the
Cheng-Prusoﬀ equation. Another 20 aporphines displayed pKi values
between 6.9 and 6.0 (IC50 < 5.5 μM, Fig. 3A).
Potent compounds clustered in several chemical series (Fig. 3A,
inset). These analogs typically possessed methoxy modiﬁcations on
aporphine rings A (C-1, C-2 or C-3 position) or D (C-9 and/or C-10
position) - either as “open” (as seen with nuciferine, compound 4b) or
“closed” dioxolane ring groupings (as seen with nantenine. Compound
2a). Other substitutions were identiﬁed that were poorly tolerated.
These included, (i) addition of bulky substituents to the aporphine nitrogen on ring B (Fig. 3B), (ii) unsaturation of the ring C, C-6a – C-7
bond: D-glaucine and L-nuciferine were antagonists with respective
pKis of 6.8 and 7.1, but dehydroglaucine and dehydronuciferine were
both inactive (Fig. 3C) and (iii) substitution of the C-3 position on ring
A (Fig. 3D).

expressing Sm.5HTRL (Fig. 1A). This increase was dose-dependent
(EC50 94 ± 18 nM) and not observed in cells expressing the GloSensor
22-F reporter alone (Fig. 1B). The sensitivity and selectivity of this response was explored for three classes of heterocyclic scaﬀolds – tryptamine derivatives, aporphines and protoberberines. The core structures of these groups, and scaﬀold numbering nomenclature, are shown
in Fig. 1C.
3.1. Modiﬁcations of the tryptaminergic pharmacophore impair agonist
activity Sm.5HTRL
First, various tryptamine derivatives were selected based on their
activity at mammalian serotonergic GPCRs: the majority of which were
substituted at the terminal amine and/or the C-5 position. For example,
5-carboxamidotryptamine (5-CT) and 5-methoxytryptamine (5-MeOT)
bind to and are potent full agonists at the mammalian 5-HT7 receptors
(Bard et al., 1993; Shen et al., 1993) that are orthologous to Sm.5HTRL
(Patocka et al., 2014; Chan et al., 2016c). N-methylserotonin, methylated at the terminal nitrogen, is also a full agonist at mammalian 5HT7 receptors (Powell et al., 2008).
In the Sm.5HTRL activity assay, the terminal amine of 5-HT accommodated the addition of methyl groups: both N-methylserotonin
(N-MS) and bufotenine (5-OH-DMT) elevated cAMP with an Emax of
113 ± 28% and 99 ± 34% relative to 5-HT, respectively (Fig. 2A).
However, while the single methyl substitution on N-MS had little eﬀect
on potency (EC50 154 ± 11 nM, compared to 94 ± 18 nM for 5-HT),
the dimethyl substitution on 5-OH-DMT decreased potency by an order
of magnitude (EC50 2.4 ± 0.2 μM). α-methylserotonin (αMS), methylated at the α position of the ethylamine side chain, was a low potency,
partial agonist (Emax of 59 ± 2% relative to 5-HT; Fig. 2A).
In contrast, the 5-OH group present on serotonin was poorly tolerant
to modiﬁcation. Tryptamine (‘T’, Fig. 2B), which is unsubstituted at the
C-5 position, displayed negligible activity at Sm.5HTRL. Substitutions at
the C-5 position with amide or methoxy groups to produce 5-carboxamidotryptamine (5-CT) and 5-methoxytryptamine (5-MeOT) respectively, were poorly tolerated. Both compounds were inactive at
Sm.5HTRL (Fig. 2B). Smaller C-5 substitutions, as seen in 5-methyltryptamine (5-MT) or 5-bromotryptamine (5-BrT), were better tolerated
as these compounds displayed partial agonist activity (Fig. 2B). All
compounds tested harboring dual substitutions at both the C-5 and
terminal amine positions compared with 5-HT were inactive at
Sm.5HTRL. These analogs included the psychedelic tryptamine derivatives N,N-diallyl-5-methoxy tryptamine (5-MeO-DALT), 5-methoxyN,N-dimethyltryptamine (5-MeO-DMT), N-methyltryptamine (N-MT)
and N,N-dimethyltryptamine (DMT, Fig. 2C). None of the compounds
identiﬁed as Sm.5HTRL agonists displayed activity against HEK293 cells expressing the GloSensor-22F reporter alone (Supplemental
Fig. 1).

3.3. Functional characteristics of the protoberberine scaﬀold at Sm.5HTRL
Protoberberines are another class of tetracyclic benzylisoquinolines
that display antagonism at Sm.5HTRL. Rotundine is a constituent of
traditional Chinese herbal medicine preparations, with activity against
both cestodes (Das et al., 2009; Gogoi and Yadav, 2017) and schistosomes (Chan et al., 2016c). We previously identiﬁed racemic D/L-rotundine) as an antagonist at Sm.5HTRL and showed this compound
inhibited movement of adult worms (Chan et al., 2016c). Given these
observations, we explored the structure-activity proﬁle of protoberberines against Sm.5HTRL in greater detail, screening 28 molecules
(Supplemental Table 1), with a focus on structures sharing a high degree of similarity with rotundine (Fig. 4A).
Racemic D/L-rotundine was a potent antagonist at Sm.5HTRL (pKi
7.2). This activity was due to the L-rotundine enantiomer, as D-rotundine was inactive (Fig. 4B&C). Palmatine, which resembles rotundine but contains a quaternary amine (Fig. 4A), was also inactive
(Fig. 4B&C). Closure of ring substituent methoxy groups into dioxolane
rings also resulted in a loss of activity, as observed comparing rotundine
to canadine or tetrahydrocoptisine. Shifting the placement of the D-ring
methoxy groups (rotundine verses xylopinine) also decreased potency
at Sm.5HTRL. Several compounds screened possessed an open protoberberine C-ring, retaining the benzylisoquinoline core (laudanosine,
papaverine, papaveraldine). None of these showed any inhibition at
Sm.5HTRL (Supplemental Table 1). Again, none of the benzylisoquinoline compounds that inhibited 5-HT evoked luminescence in
Sm.5HTRL expressing cells blocked forskolin-evoked signals, indicating
that drug action was not due to toxicity or other mechanisms inhibiting
cAMP generation (Supplemental Fig. 1).

3.2. Functional characteristics of the aporphine alkaloid scaﬀold at
Sm.5HTRL
The aporphine alkaloids are tetracyclic benzylisoquinolines that
exhibit a range of activities at mammalian bioaminergic GPCRs
(Cabedo et al., 2009; Harding, 2016). Numerous naturally occurring
(Indra et al., 2002; Farrell et al., 2016) and synthetic (Linnanen et al.,
2001; Chaudhary et al., 2009, 2011; Kapadia and Harding, 2015)
aporphines are potent antagonists of mammalian serotonergic receptors, and preliminary structure-activity proﬁling of this chemical
series has been performed on Sm.5HTRL (Chan et al., 2016a). Based on
these data, we expanded our study to encompass 89 aporphine structures.
Compounds containing the aporphine core ring structure were curated from the NCI and TimTec natural product libraries (Supplemental
Table 1) and screened at an initial concentration of 10 μM. None of the
tested aporphines showed agonist activity. Full concentration-

3.4. Sm.5HTRL ligands alter the mobility of adult schistosomes cultured ex
vivo
Sm.5HTRL is required for worm movement (Patocka et al., 2014)
and Sm.5HTRL ligands can stimulate or block movement in larval
schistosomules and adult worms (Chan et al., 2016a, 2016c). Therefore,
we examined the eﬀects of several substituted tryptamines (Sm.5HTRL
agonists) and benzylisoquinolines (Sm.5HTRL antagonists) against
adult schistosomes to assess whether these hits were active and whether
they recapitulated structure-activity proﬁles observed against
Sm.5HTRL in vitro.
Tryptaminergic Sm.5HTRL agonists stimulated worm movement,
although with decreased potency relative to results from in vitro cAMP
552
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Fig. 2. Structure-activity relationship of tryptamine derivatives at Sm.5HTRL. (A) Action of tryptamine analogs with modiﬁcations to the ethylamine group
highlighted on the inset structure of serotonin (5-HT). N-MS = N-methylserotonin, 5-HO-DMT = bufotenine, αMS = α-methylserotonin. (B) Eﬀect of analogs with
modiﬁcations to the highlighted tryptamine C-5 position of 5-HT (5-MT = 5-methyltryptamine, 5-BrT = 5-bromotryptamine, 5-MeOT = 5-methoxytryptamine,
T = tryptamine, 5-CT = 5-carboxamidotryptamine), or (C) both the C-5 and terminal amine groups (5-MeO DALT = N,N-diallyl-5-methoxytryptamine, 5-MeO
DMT = 5-methoxy-N,N-dimethyltryptamine, DMT = N,N-Dimethyltryptamine, N-MT = N-Methyltryptamine). Values expressed relative to the maximal 5-HT response (scaled to 100% on all Y-axes).

tested on live worms to assess whether these compounds inhibited 5-HT
evoked movement. Worms were incubated in compound for 1 h, after
which a maximal dose of serotonin (200 μM) was added to stimulate
motility. Several aporphines resembling nuciferine were studied.
Nuciferine was the most potent antagonist of worm movement, inhibiting 5-HT evoked movement at concentrations as low as 100 nM
(Fig. 5B). Compound phar025462, a nuciferine derivative with a
charged nitrogen and a closed dioxolane ring in place of methoxy
groups, and compound 785177, which substitutes the nuciferine A-1
methoxy with an hydroxy group, both inhibited 5-HT evoked movement, albeit with lower potency in the 1–10 μM range (Fig. 5B). The
compound MDO-NPA, which potently inhibited Sm.5HTRL (pKi = 7.0),
was relatively inactive on adult worms with inhibition of 5-HT not

assays (Fig. 5A). Consistent with assays on Sm.5HTRL, substitution of
the terminal amine was tolerated. N-methylserotonin (N-MS) was a full
agonist increasing movement by 252 ± 9%, comparable to the 5-HT
evoked-increase of 224 ± 17%. The indole C-5 position was amenable
to slight modiﬁcations. 5-methyltryptamine (5-MT) stimulated movement, but only at high concentrations in the hundreds of micromolar. 5methoxytryptamine (5-MeOT) stimulated movement, which contrasts
with a lack of agonist activity at Sm.5HTRL in vitro (Figs. 5A and 2B). 5Carboxamidotryptamine (5-CT) did not stimulate movement, consistent
with this compound being inactive at Sm.5HTRL. DMT, which is modiﬁed at both the indole C-5 and terminal amine, also had no eﬀect on
worm movement, mirroring the observed lack of activity at Sm.5HTRL.
Next, the aporphine and protoberberine Sm.5HTRL antagonists were
553

IJP: Drugs and Drug Resistance 8 (2018) 550–558

J.S. Marchant et al.

Fig. 3. Structure-activity relationship of aporphine alkaloids at Sm.5HTRL. (A) Aﬃnity of 84 aporphines screened against Sm.5HTRL, with pKi estimated using
the Cheng-Prusoﬀ equation. Inset - tree resulting from hierarchical clustering of structures, with most potent hits (pKi > 7.0) denoted with black symbols, and hits
with pKi between 6.0 and 6.9 denoted with gray circles. Bottom – structures of the nine most potent compounds. (B) Structure activity proﬁle of a nantenine-like
aporphine series with modiﬁcations to the basic B-6 nitrogen. (C) Eﬀect of dehydrogenation of the C-6a/C-7 bond of either D-glaucine or L-nuciferine. (D) Eﬀect of
various modiﬁcations to the D-glaucine A4 position resulting in a loss of activity at Sm.5HTRL.

surpassing 50% even at 10 μM (Fig. 5B).
Of the protoberberines, the Sm.5HTRL antagonist L-rotundine, the
inactive analog D-rotundine and the closely related palmatine were
screened on live worms. As expected, L-rotundine inhibited 5-HT
evoked movement at concentrations ≥1 μM, while D-rotundine and
palmatine showed no inhibition of 5-HT evoked movement at concentrations as high as 50 μM (Fig. 5C).

and benzylisoquinoline natural products as serotonergic ligands
(Cabedo et al., 2009; Nichols, 2012; Harding, 2016) and antiparasitic
compounds (Bonne, 1919; Iwasa et al., 1999; Nkwengoua et al., 2009;
Das et al., 2009; Shahinas et al., 2012; Gogoi and Yadav, 2017), we
performed a more detailed exploration of the properties of these
pharmacophores that determine their eﬃcacy as Sm.5HTRL ligands and
activity against ex vivo cultured parasites.

4. Discussion

4.1. Tryptaminergic ligand SAR at Sm.5HTRL

These data highlight the structure-activity proﬁle of tryptamineand benzylisoquinoline-based analogs on a schistosome 5-HT receptor
(Sm.5HTRL) that controls worm movement. 5-HT has long been recognized as an important regulator of schistosome neuromusculature
(Hillman et al., 1974; Tomosky et al., 1974; Patocka et al., 2014), and
5-HT receptors have been advanced as appealing targets for anthelmintic drug development (Mansour, 1979, 1984; Geary et al., 1992).
The successful functional expression and miniaturization of a
Sm.5HTRL proﬁling assay has enabled high-throughput compound
screens to identify ligands with potential anti-schistosomal activity
(Chan et al., 2018). Given these data validating Sm.5HTRL as a viable
anti-schistosomal drug target, and the precedent of both tryptaminergic

Substituted tryptamines with modiﬁcations to the C-5 and terminal
amine often display agonist activity against mammalian serotonergic
receptors (Plassat et al., 1993; Shen et al., 1993; Shulgin, 1997; Powell
et al., 2008; Nichols, 2012). Compounds with subtle modiﬁcations to
the terminal amine retained agonist activity at Sm.5HTRL (Fig. 2A), but
the pharmacophore was poorly tolerant to substitution at the C-5 position (Fig. 2B). The poor activity of 5-CT and 5-MeOT at Sm.5HTRL
contrasts with the action of these ligands as full agonists at the orthologous human 5-HT7 receptor (Plassat et al., 1993). Given that the
amino acid sequence of Sm.5HTRL shares just 40% similarity with the
human ortholog, it is not surprising that the two GPCRs exhibit unique
pharmacological sensitivities. A possible reason for the inactivity of the
554
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Fig. 4. Structure-activity relationship of protoberberine alkaloids at Sm.5HTRL. (A) Structures of
various protoberberines with structural similarity to
the Sm.5HTRL antagonist D/L-rotundine. (B) Aﬃnity
of protoberberine ligands at Sm.5HTRL, pKi estimated using the Cheng-Prusoﬀ equation (structures
and pKi for all protoberberines screened are listed in
Supplemental Table 1). (C) Concentration response
curves for rotundine (racemate = solid blue symbol,
L-enantiomer = solid
red
symbol,
D-enantiomer = solid black symbol) and related compounds (symbols pair with structures shown in A.).
(For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the Web version of this article.)

antagonists at Sm.5HTRL and inhibitors of schistosome movement
prompting exploration of compounds containing these ring systems in
further detail. A thorough analysis of 117 benzylisoquinoline structures
identiﬁed only antagonist hits. The strictly antagonist proﬁle associated
with this scaﬀold (Figs. 3 and 4) contrasts with the agonist/partial
agonist proﬁle of the tested tryptamine derivatives (Fig. 2) and the
mixed agonist/antagonist proﬁle of ergot alkaloids reported elsewhere
(Chan et al., 2018).
Of the aporphine compounds tested, the most potent antagonists
had a 1,2,9,10- substituted pattern, with methoxy groups or a dioxolane
ring attached to the A and D rings of the aporphine core (nantenine,
boldine, D-glaucine). The stereochemistry of the B6-B6a bond did not
seem crucial –the levo structure L-nuciferine and dextro structures Dglaucine, boldine and nantenine were all potent antagonists (Fig. 3).
However, saturation of the C ring at this position was important; dehydrogenation of the C-6a – C-7 bond of either D-glaucine or L-nuciferine resulted in a loss of activity (Fig. 3C). In addition to nuciferine,
boldine and D-glaucine, which were previously identiﬁed as Sm.5HTRL
antagonists (Chan et al., 2016a), we have shown that nantenine and
ocoteine-like aporphines are also potent Sm5HTRL antagonists (pKi >
7.0, Fig. 3).
The protoberberine skeleton is similar to the aporphine skeleton –
both share a benzylisoquinoline core. Consequently, it is unsurprising
that like the aporphines, all active protoberberine compounds were

C-5 substituted tryptamines at Sm.5HTRL is that mutation of the glutamic acid at the 7.35 position of the human 5-HT7 receptor abrogates
5-CT binding and function (Impellizzeri et al., 2015). This site varies in
the schistosome receptors (phenylalanine), as well as the invertebrate
C. elegans SER-7 receptor (aspartic acid) which is also refractory to 5-CT
(Hobson et al., 2006). This diﬀerence, as well as the ﬁnding that neither
DMT or related derivatives were active on Sm.5HTRL (Fig. 2C), despite
their activity on mammalian serotonergic receptors (Shen et al., 1993;
Keiser et al., 2009; Ray, 2010; Cozzi and Daley, 2016), advances our
pharmacological understanding of the unique pharmacological signatures of host and parasite receptors. Other examples include the ergot
alkaloid ergotamine, a potent antagonist at the human 5-HT7 receptor
(Wacker et al., 2013) but full agonist at Sm.5HTRL (Chan et al., 2018),
as well as the commonly used 5-HT7 chemical probe SB-269970, which
is inactive at Sm.5HTRL (Chan et al., 2016c). These data emphasize the
need for considerable caution when using pharmacological probes developed against mammalian targets to study invertebrate GPCRs, while
revealing opportunities for developing parasite-selective ligands.

4.2. Determinants of benzylisoquinoline antagonism of schistosome
serotonin receptors
Our previous work identiﬁed the benzylisoquinolines rotundine
(Chan et al., 2016c) and nuciferine (Chan et al., 2016a) as potent
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was ∼10 times less potent that rotundine, indicating that the stereochemistry of the methoxy groups are critical. This again diﬀers from the
aporphines, which accommodated various methoxy group placement
around the A and D rings.

4.3. Correlation of Sm.5HTRL pharmacology with worm movement ex vivo
Schistosome movement is regulated by serotonergic signaling
through Sm.5HTRL (Patocka et al., 2014), and there is a correlation
between drug activity at this receptor and movement of parasites cultured ex vivo, with Sm.5HTRL agonists stimulating movement and
Sm.5HTRL antagonists inhibiting movement (Chan et al., 2016a, 2016c,
2018). Trypaminergic ligands were agonists at Sm.5HTRL, and substitutions that eliminated activity at Sm.5HTRL also eliminated the
ability of the same compounds to stimulate worm movement (5-CT and
DMT, Fig. 2B&C and Fig. 5A). Similarly, substitutions that were tolerated in Sm.5HTRL cAMP assays were also generally tolerated in
movement assays. For example, N-MS (diﬀering from 5-HT by addition
of a methyl group to the terminal amine) mirrored 5-HT in both assays.
Modiﬁcation of the tryptamine C-5 position resulted in compounds that
were displayed impaired activity relative to 5-HT. Several compounds
stimulated movement of worms ex vivo, but were inactive against
Sm.5HTRL. For example, 5-MeOT did not potently activate Sm.5HTRL
(Fig. 2B), but potently stimulated movement in adult worms (Fig. 5A).
While these diﬀerences may reﬂect diﬀerences between Sm.5HTRL
function in live worms versus a mammalian expression system, an alternative interpretation is that 5-MeOT stimulates movement through
other serotonin/bioaminergic GPCRs (Zamanian et al., 2011). This explanation can be tested as other schistosome GPCRs become amenable
to functional proﬁling.
Reciprocally some compounds that are active against Sm.5HTRL
show poor eﬃcacy in ex vivo worm movement assays, perhaps due to
pharmacokinetic variables such as whether the ligand is free to diﬀuse
through the parasite tegument, is a substrate for active transporters
such as SERT (Patocka and Ribeiro, 2007), or is degraded by worm
enzymes such as monoamine oxidase (Nimmo-Smith and Raison, 1968).
These variables may account for the right shifted dose response curves
of serotonin in cell based cAMP assays (Fig. 1A) relative to worm
movement assays (Fig. 5A). Similarly, benzylisoquinoline Sm.5HTRL
antagonists were less potent on worms (Fig. 5B&C) than in cell-based
cAMP assays (Figs. 3 and 4).
Human and parasite bioaminergic GPCRs are proven druggable
targets (Evans and Gee, 1980; Hauser et al., 2017), and exploration of
bioaminergic targets is a promising route for novel anti-schistosomal
drug development (Wang et al., 2017; Camicia et al., 2018; Chan et al.,
2018; Hahnel et al., 2018). One barrier to this work has been the
functional expression of schistosome GPCRs in scalable assays that
permit their thorough pharmacological characterization. While part of
this diﬃculty may stem from the divergence of schistosome GPCRs
relative to established model organisms (Sm.5HTRL has a 25% and 24%
amino acid identity to human 5-HTR7 and C. elegans SER-7, respectively), this lack of conservation may also oﬀer the opportunity to
achieving a degree of pharmacological selectivity. This is supported by
the structure-activity proﬁles outlined here, which highlight speciﬁc
modiﬁcations that confer aﬃnity as well as selectivity between worm
and human orthologs. Expanding this approach to other schistosome
GPCRs and other bioactive pharmacophores will be informative for
future anthelmintic pharmacophore development and drug discovery
initatives.

Fig. 5. Eﬃcacy of tryptamine and benzylisoquinoline ligands on adult S.
mansoni cultured ex vivo. (A) Quantiﬁed changes in movement of adult
parasites exposed to escalating doses of 5-HT (black, bold) and various other
substituted tryptamine derivatives. Right – structure of serotonin, with highlighted regions corresponding to substituted regions at the C-5 position (red; 5MeOT, 5-MT, 5-BrT, 5-CT), or the terminal amine (blue, N-MS). (B) Eﬀect of
various concentrations of nuciferine-like aporphines on 5-HT evoked movement. Right – structure of nuciferine, with highlighted regions corresponding to
substituted regions at the 1,2 positions of the A ring (red, compound 785177
and phar025462) and methyl group on the B ring (blue, MDO-NPA). (C) Eﬀect
of various concentrations of protoberberines on 5-HT evoked movement. Right
– structure of L-rotundine, with highlighted regions corresponding to the stereocenter in the protoberberine core and C-ring substitutions on D-rotundine
and palmatine. SMILES for all compounds are provided in Supplementary
Table 1. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the Web version of this article.)

antagonists. However, unlike the aporphines, the chirality of the stereocenter adjacent to the nitrogen atom seems crucial. For the antagonist D/L-rotundine, the L-rotundine enantiomer was active and Drotundine displayed no activity at Sm.5HTRL (Fig. 4). This stereochemistry mirrors rotundine's antagonism of mammalian bioaminergic
GPCRs, where L-rotundine is the active enantiomer antagonizing
mammalian dopamine D1 (Mantsch et al., 2007) and serotonin 5HT1A
receptors (Mi et al., 2017). Like the active aporphines, L-rotundine
possesses methoxy groups on the A and D rings. However, in the case of
the protoberberines, formation of dioxolane rings - closing the methoxy
positions on the A ring to produce canadine, or both the A and D rings
to produce tetrahydrocopsitine - resulted in inactive compounds. The
structure of xylopinine is identical to rotundine except for the movement of one methoxy from the D9 to the D11 position, but xylopinine
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